German services activity underperformed sharply at 50.2 versus a forecast of 52.3, signaling a weakening outlook despite previous strength. France posted a modest gain to 46.6, slightly above ...

Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...

Welcome to CureVac fourth-quarter and full year 2024 financial results and business update call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to ...

It shows that resistance is not driven only by genetic mutations but may also involve adaptive changes in the cell's internal ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier. GSK is fronting £38.5 million (nearly $50 million), in a partnership with ...

3 The impact of ultrasound on peripheral nerve injury 3.1 The ... and enhance the secretion of NGF. Nevertheless, the signaling pathways through which they facilitate nerve regeneration may differ, ...

Key Laboratory for Food Microbial Technology of Zhejiang Province, School of Food Science and Biotechnology, Zhejiang Gongshang University, Xiasha, Hangzhou, Zhejiang 310018, PR China ...

Numerous studies have highlighted the role that benign non-immune cells exert on tumor progression and potential tumor-promoting mechanisms via multiple signaling pathways and ... and treatment of ...

The adjustment in the price target to $115.00 from $120.00 accompanies this upgraded outlook, signaling a nuanced view of the bank ... allowing for the repurchase of up to 3 million shares, ...

GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to accelerate drug development and halt the nation’s slide down global life ...

ALPK3 (α protein kinase 3) is an atypical kinase highly expressed in human and murine hearts. Biallelic loss‐of‐function mutations in ALPK3 lead to pediatric cardiomyopathy. The specific stages at ...